Statin therapy and decreased incidence of positive Candida cultures among patients with type 2 diabetes mellitus undergoing gastrointestinal surgery

Mayo Clinic Proceedings

Volumn 85, Issue 12, 2010, Pages 1073-1079

  Spanakis, Elias K ^a,b   Kourkoumpetis, Themistoklis K ^a   Livanis, Grigorios ^c   Peleg, Anton Y ^d,e,f   Mylonakis, Eleftherios ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b ST ELIZABETH'S MEDICAL CENTER   (United States)

^c NORTHEASTERN UNIVERSITY   (United States)

^d ALFRED HOSPITAL   (Australia)

^e MONASH UNIVERSITY   (Australia)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ATORVASTATIN; CORTICOSTEROID; FLUINDOSTATIN; IMMUNOSUPPRESSIVE AGENT; INSULIN; MEVINOLIN; ORAL ANTIDIABETIC AGENT; PRAVASTATIN; PREDNISONE; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CANDIDA; CANDIDIASIS; COMORBIDITY; DIET THERAPY; FEMALE; FUNGUS CULTURE; GASTROINTESTINAL SURGERY; HAZARD RATIO; HIGH RISK PATIENT; HOSPITAL ADMISSION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRESCRIPTION; RETROSPECTIVE STUDY; TOTAL PARENTERAL NUTRITION;

EID: 78650078617     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/mcp.2010.0447     Document Type: Article

References (28)

1. Cole GT, Halawa AA, Anaissie EJ. The role of the gastrointestinal tract in hematogenous candidiasis: from the laboratory to the bedside. Clin Infect Dis. 1996;22(suppl 2):S73-S88.
2. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003; 348(16):1546-1554.
3. Hospital Infections Program; National Center for Infectious Diseases; Centers for Disease Control and Prevention (CDC); Public Health Service; US Dept of Health and Human Services (DHS). National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990-May 1999, issued June 1999. Am J Infect Control. 1999;27(6):520-532.
4. Gudlaugsson O, Gillespie S, Lee K, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis. 2003;37(9):1172-1177. (Pubitemid 37372504)
5. Mann D, Reynolds K, Smith D, Muntner P. Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines. Ann Pharmacother. 2008;42(9):1208-1215.
6. Sun HY, Singh N. Antimicrobial and immunomodulatory attributes of statins: relevance in solid-organ transplant recipients. Clin Infect Dis. 2009; 48(6):745-755.
7. Parks LW, Casey WM. Physiological implications of sterol biosynthesis in yeast. Annu Rev Microbiol. 1995;49:95-116.
8. Krause W, Matheis H, Wulf K. Fungaemia and funguria after oral administration of Candida albicans. Lancet. 1969;1(7595):598-599.
9. Cohen R, Roth FJ, Delgado E, Ahearn DG, Kalser MH. Fungal flora of the normal human small and large intestine. N Engl J Med. 1969; 280(12):638-641.
10. Stone HH, Geheber CE, Kolb LD, Kitchens WR. Alimentary tract colonization by Candida albicans. J Surg Res. 1973;14(4):273-276.
11. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Risk factors for hospital-acquired candidemia: a matched case-control study. Arch Intern Med. 1989;149(10):2349-2353. (Pubitemid 19258182)
12. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg. 1994;220(6):751-758. (Pubitemid 24376373)
13. Olaechea PM, Palomar M, Leon-Gil C, et al. Economic impact of Candida colonization and Candida infection in the critically ill patient. Eur J Clin Microbiol Infect Dis. 2004;23(4):323-330. (Pubitemid 38669943)
14. Santos Arrontes D, Fernandez Acenero MJ, Garcia Gonzalez JI, Martin Munoz M, Paniagua Andres P. Survival analysis of clear cell renal carcinoma according to the Charlson comorbidity index. J Urol. 2008;179(3):857-861. (Pubitemid 351208417)
15. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383. (Pubitemid 17055592)
16. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika. 1982;69(1):293-241.
17. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-3421.
18. Wikhe K, Westermeyer C, Macreadie IG. Biological consequences of statins in Candida species and possible implications for human health. Biochem Soc Trans. 2007;35(pt 6):1529-1532.
19. Macreadie IG, Johnson G, Schlosser T, Macreadie PI. Growth inhibition of Candida species and Aspergillus fumigatus by statins. FEMS Microbiol Lett. 2006;262(1):9-13. (Pubitemid 44212883)
20. Chin NX, Weitzman I, Della-Latta P. In vitro activity of fluvastatin, a cholesterol-lowering agent, and synergy with flucanazole and itraconazole against Candida species and Cryptococcus neoformans. Antimicrob Agents Chemother. 1997;41(4):850-852. (Pubitemid 27150546)
21. McFarlane SI, Muniyappa R, Francisco R, Sowers JR. Clinical review 145: pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab. 2002;87(4):1451-1458. (Pubitemid 34615220)
22. Hackam DG, Mamdani M, Li P, Redelmeier DA. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet. 2006;367(9508):413-418. (Pubitemid 43184262)
23. Martin CP, Talbert RL, Burgess DS, Peters JI. Effectiveness of statins in reducing the rate of severe sepsis: a retrospective evaluation. Pharmacotherapy. 2007;27(1):20-26.
24. Kruger P, Fitzsimmons K, Cook D, Jones M, Nimmo G. Statin therapy is associated with fewer deaths in patients with bacteraemia. Intensive Care Med. 2006;32(1):75-79. (Pubitemid 43039379)
25. Kopterides P, Falagas ME. Statins for sepsis: a critical and updated review. Clin Microbiol Infect. 2009;15(4):325-334.
26. Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol. 2006;6(5):358-370.
27. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286(1):64-70. (Pubitemid 32606333)
28. Forrest GN, Kopack AM, Perencevich EN. Statins in candidemia: clinical outcomes from a matched cohort study. BMC Infect Dis. 2010;10:152.